Contact Us:
GSE Manuals
email gsetraining@gmail.com
Our Business Hours
24/7
Tesla's Cybertruck Sets Internet Abuzz (Again) As Musk Reveals Features On Twitter (Tue, 25 Feb 2020)
>> Read more
How the IRS Knows If You Cheat on Your Taxes (Mon, 24 Feb 2020)
>> Read more
Italy, Iran Cases Jump; Drug Result Due in April: Virus Update (Tue, 25 Feb 2020)
(Bloomberg) -- Iran
reported a total of 15 deaths from the coronavirus, the most fatalities outside China. Italy, the outbreak’s epicenter in Europe, said infections in the Lombardy region rose to 206 from 172. The
country might seek flexibility on some budget targets.Earlier on Tuesday, South Korea reported 84 new infections for a total tally of 977, making it the country with most cases outside of China. The
U.S., Japan and Hong Kong issued travel warnings for South Korea, while the United Arab Emirates banned flights to all Iranian cities.The head of the World Health Organization had earlier called the
new cases “deeply concerning,” but said the outbreak isn’t yet a pandemic. China plans to release results from clinical trials of a Gilead Sciences Inc. drug in April.Key DevelopmentsChina death toll
2,663, up 71; total mainland cases at 77,658South Korea death toll at 10, countries issue travel warningsTrump administration seeks $2.5 billion in supplemental fundingHong Kong schools extend
closure, Indonesia plans stimulusClick VRUS on the terminal for news and data on the coronavirus and here for maps and charts. For analysis of the impact from Bloomberg Economics, click here.Mideast
Cases Rise, Flight Restrictions in Place (6 p.m. HK)Iran reported 34 new cases, for a total of 95, and a death toll of 15. Bahrain reported six new cases, while Kuwait has an additional three cases.
So far, there are about 130 confirmed cases in the Middle East and all of them are linked to Iran.The U.A.E. banned travel to all cities in Iran and has already suspended all flights to and from
China, except Beijing. Kuwait, which has already stopped flights to Iran, on Monday suspended travel to South Korea, Thailand, Italy and Iraq.Singapore Eases Rules for Chinese Workers in More Sectors
(6 p.m. HK)Singapore will loosen restrictions on Chinese work-permit holders in the country to help businesses in manufacturing and services industries that have been hit by labor disruptions during
the coronavirus outbreak.For six months beginning March 2, the Ministry of Manpower will allow companies in those sectors to hire Chinese workers who are already in the country, with the agreement of
their existing employers. Currently, businesses can only hire Chinese work-permit holders once they have left Singapore.Thailand’s Tourism Income Tumbled in January (5:55 p.m. HK)A slump in
Thailand’s foreign tourism income underlines the damage being inflicted on its economy. Receipts tumbled 3.6% in January from a year earlier to $6 billion), dragged down by a 10% slide in outlays by
Chinese visitors.HK Exports Slid Most in Decade in Jan. Ahead of Virus (5:26 p.m. HK)Hong Kong’s exports plummeted the most in more than a decade in January, as the government warned of further
weakness in the coming months with the full force of disruptions from the coronavirus outbreak still ahead. Exports sank 22.7% in January from year-ago levels to HK$269.4 billion ($34.6 billion), the
most since February 2009.Weihai to Quarantine People From Japan, S. Korea (5:22 p.m. HK)China’s Weihai city in Shandong province will quarantine people coming from Japan and South Korea for 14 days,
effective Feb. 25. People will be quarantined in hotels for free.Separately, Hangzhou, home to e-commerce giant Alibaba and other tech firms, will offer subsidies to people who choose to relocate to
the city for work during the epidemic. 85European Corporate Bond Market in Deep Freeze (4:50 p.m. HK)Global borrowers shunned Europe’s corporate debt market for a second day as a cluster of new
coronavirus cases in Italy sent yields sharply higher, bringing sales of new bonds to a near standstill.ING Groep’s downsized debt offering is the only deal priced so far this week, which had been
expected to deliver more than 20 billion euros ($22 billion) of sales, according to a Bloomberg News survey. Non-financial borrowers are nowhere to be seen, with Spain the only sovereign issuer
braving the market so far on Tuesday.Indonesia Unveils $718 Million Stimulus (4:46 p.m. HK)Indonesia will waive taxes of hotels and restaurants in ten tourist destinations for three months. State-run
oil retailer Pertamina will sell jet fuels to airlines at discounted prices, and the federal government will give grants to local governments as revenue from tourism slumpsGilead’s Drug Leads Global
Race for Treatment (3:40 p.m. H.K.)China said it will release results on April 27 of a clinical trial of Gilead Sciences’s remdesivir drug that the World Health Organization said may be the only
effective treatment so far for the disease.The trials of the experimental medication involved 761 patients in Wuhan, the city where the virus originated.Italian Tourist on Spanish Hotspot Tenerife
Tests Positive (2:27 p.m. H.K.)An Italian staying on the Spanish island of Tenerife tested positive for the virus and a second test to confirm the case will be carried out in Madrid, the government
said. The case would be Spain’s third and the first on the island, one of Europe’s top holiday destinations for winter sun. Tenerife, the largest of the Canary Islands, attracted more than 5.7
million tourists last year.The tourist, a doctor, had come from Lombardy, a region of northern Italy that is a focus of an outbreak of the virus, Efe news service reported. Spain’s two previously
confirmed patients no longer have the infection.Hong Kong Schools Extend Closure Until April 20 (2:12 p.m. H.K.)Hong Kong extended school closures by four weeks until at least the end of the Easter
break. The city will hold written university exams as scheduled from March 27 but postponed oral tests, Education Secretary Kevin Yeung said in a briefing.Students in the city, which has 81 confirmed
coronavirus cases, haven’t attended classes since the Lunar New Year break began in late January.In a Feb. 12 letter to Hong Kong Chief Executive Carrie Lam, the city’s international schools warned
that a prolonged shutdown could cause families to leave Hong Kong and force some schools to shut permanently.Japan Cruise Ship Death Reported (11:14 a.m. HK)A fourth passenger from the Diamond
Princess cruise ship in Japan has died, NHK reported.The patient was in his 80s and had the coronavirus, according to NHK. Three others from the ship have also died, though pneumonia was cited as the
cause of one of the deaths.The cruise ship that was quarantined for 14 days off of Yokohama has been the source of about 700 infections.Trump Administration Seeks $2.5 Billion to Battle Virus (9:41
H.K.)The Trump administration said it has asked Congress for $2.5 billion in supplemental funding to battle the spread of the coronavirus. More than $1 billion of the money would be go toward
creating, manufacturing and distributing a vaccine, according to a person familiar with the matter.The money would also be used to “support preparedness and response activities and to procure much
needed equipment and supplies,” said Rachel Semmel, a spokeswoman for the Office of Management and Budget.House Appropriations Committee Chair Nita Lowey said the requested sum “is woefully
insufficient.”Singapore’s Temasek Freezes Pay Amid Virus (9:35 a.m. H.K.)Temasek Holdings Pte, Singapore’s state-owned investment firm, said it will implement a company-wide wage freeze and ask
senior management to take bonus cuts and voluntary pay reductions starting in April amid the coronavirus outbreak.About 26% of Temasek’s holdings were in China as of March 2019, including
multibillion-dollar stakes in Alibaba Group Holding Ltd. and Industrial & Commercial Bank of China Ltd. With the money saved, Temasek said it will donate to staff volunteer initiatives and
support the community as needed through unspecified measures.CDC Warns Americans on Korean Travel (8:05 a.m. HK)The U.S. Centers for Disease Control and Prevention warned Americans to avoid all
non-essential travel to South Korea as the novel coronavirus is spreading widely throughout the community there.Older adults and people with chronic medical conditions may be at increased risk from
the pathogen, and there is limited access to adequate medical care in affected areas, the agency said. The level 3 warning, the CDC’s highest, matches the caution it previously placed on China.The
CDC previously issued lower-level alerts for Italy, Iran and Japan, telling travelers to take extra care and consider postponing non-essential travel.Singapore Air to Cut More Flights (7:59 a.m.
HK)Singapore Airlines will make more temporary adjustments to flights across its network due to weak demand because of the coronavirus outbreak, the company says on its website. The adjustments will
result in a 7.1% reduction in scheduled capacity from February to the end of May.\--With assistance from Charles Penty.To contact Bloomberg News staff for this story: Jeff Sutherland in Tokyo at
jsutherlan13@bloomberg.netTo contact the editors responsible for this story: Rachel Chang at wchang98@bloomberg.net, Adam MajendieFor more articles like this, please visit us at
bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
>> Read more
J.P. Morgan: 2 “Strong Buy” Healthcare Stocks With Over 50% Upside (Mon, 24 Feb 2020)
Digitization of the
world we live in has disrupted the healthcare industry, giving rise to the healthcare information technology (IT) segment of the market. The emergence of this space and the technology it offers has
transformed the way healthcare providers and organizations care for patients. Not to mention efficiency has improved dramatically. Demand for these digital solutions isn’t expected to slow anytime
soon, with Grand View Research predicting that the digital healthcare market will expand at a CAGR of 27%, reaching $509.2 billion by 2025.Bearing this in mind, investing firm J.P. Morgan took a look
at several healthcare IT names ahead of their upcoming fourth quarter earnings releases.“Sentiment on the group has been largely favorable, with the group up 12% since Q3 earnings in November vs the
remaining Healthcare Technology & Distribution group up 14% and the SPX 8%-plus,” analyst Anne Samuel commented.In the report, the firm highlights two tickers in particular that it believes can
not only deliver solid prints, but also reward investors through 2020 and beyond. After using TipRanks’ Stock Screener tool, we found out each boasts a “Strong Buy” consensus rating from the Street,
and has a substantial upside potential from the current share price. We’re talking more than 50% here.Health Catalyst Inc. (HCAT)With its cloud-based data platform, Health Catalyst offers data and
analytics solutions to healthcare organizations. As the company gears up for its February 27 earnings release, J.P. Morgan has high hopes.The investment banking firm's analyst, Anne Samuel, notes
that she will be focused on how many new Data Operating System (DOS) clients were added during the year as well as dollar-based retention. Additionally, Samuel highlights the fact that the company
thinks the Medicity conversion opportunity is approaching an inflection point in 2020 given that this past summer, cross-sell conversations kicked off.Based on Samuel’s estimates, the analyst expects
net new customers for 2019 to land at 14, which would reflect 28% year-over-year customer growth. In terms of 2020 guidance, she is forecasting 18 net new DOS subscription customers and 7% same-store
growth, amounting to 25% DOS subscription revenue growth. However, thanks to Medicity drag, the total revenue gain is expected to come in at 22%. As a result, this brings the 2020 revenue prediction
to $186 million, which falls in line with the consensus.While Samuel does point out that HCAT operates in a highly competitive environment and that there could be an expense shift of $200,00 from Q3
into Q4, her bullish thesis remains very much intact. “We see significant white space in an $8 billion TAM, with over 20% revenue growth driven by mid-teens annual customer wins. We estimate the
company reaches EBTIDA profitability in the next four years as a maturing customer base drives incremental leverage. The model is predictable with over 90% recurring revenue, 107% net dollar-based
retention, and a sticky customer base, never having lost an all-access customer,” the analyst explained.Taking all of this into consideration, Samuel maintained both her Overweight call and $50 price
target. Should this target be met, shares could be in for a twelve-month gain of 66%. (To watch Samuel’s track record, click here)Overall, it has been relatively quiet when it comes to other analyst
activity. In the last three months, only 3 analysts have issued ratings. However, as they were all Buys, the word on the Street is that HCAT is a Strong Buy. Based on the $48.33 average price target,
shares could climb 60% higher in the next twelve months. (See Health Catalyst stock analysis on TipRanks)Livongo Health Inc. (LVGO)Moving on to the firm’s next pick, we come across Livongo Health.
For patients battling chronic health conditions, its digital health platform makes it easy to access personalized digital guidance and health coaching through a smart connected device. While the
healthcare name has experienced significant volatility, the firm remains optimistic.Ahead of its Q4 earnings release on March 2, Samuel, who also covers this stock, wrote that LVGO already “blessed
Street numbers on its Q3 call for $276 million equating to 63% year-over-year growth.” She added, “Looking at the economic value added (EVA) that they reported in Q3, a 40% conversion rate on $208
million year-to-date EVA would equate to a 70% revenue growth run rate on our math.”When the results are announced, Samuel anticipates that the Street will be paying close attention to 2020 guidance
and the sustainability of rapid growth, noting that management stated 2020 will be an “investment year”. On top of this, the analyst is hoping for an update on enrollment, pipeline for new growth and
any changes in the competitive landscape.In terms of the fourth quarter figures, Samuel is calling for revenue of $49.4 million and an EBITDA loss of $5.5 million, both of which would land within the
guided range. For 2020, the analyst expects the company to guide for $281 million in revenue, a 66% increase if achieved, gross profit margins of 72% and a fiscal 2020 EBITDA loss of $25
million.Despite the EBITDA figure being in the red, Samuel believes LVGO will be able to reach operating income profitability in 2021. Additionally, the analyst argued, “The company is minimally
penetrated in a vast and growing chronic disease market, as more than half of the U.S. population has one or more chronic conditions and an additional 4,000 Americans are diagnosed with diabetes each
day. LVGO’s rapid growth profile is attractive, and unique in Healthcare IT with our model calling for an 85% revenue CAGR over the next 3 years as the company increases its member base.”In line with
her optimistic take, Samuel kept an Overweight rating and price target of $43 on the stock. This target conveys her confidence in LVGO’s ability to climb 55% higher in the next twelve months.What
does the rest of the Street think about LVGO? As it turns out, other analysts are on the same page. With 100% Street support, the message is clear: the stock is a Strong Buy. Not to mention the
$45.67 average price target implies 64% upside potential. (See Livongo stock analysis on TipRanks)
>> Read more
Gilead Surges After WHO Comments on Virus Drug Testing (Mon, 24 Feb 2020)
(Bloomberg) -- Gilead Sciences Inc.
shares gained Monday after a senior World Health Organization official said the company’s experimental drug may be the best bet to find a treatment for the new coronavirus spreading around the
globe.Gilead’s compound, remdesivir, has been rushed into a clinical trial in China, where the illness has infected tens of thousands of people. WHO officials have said results could be available
within weeks.Remdesivir is the “one drug right now that we think may have efficacy,” Bruce Aylward, an assistant director-general at the World Health Organization, said at a briefing in Beijing. WHO
officials and international scientists are in the country assessing the outbreak.Gilead shares rose 4.6% to $72.90 on Monday, the highest closing level since October 2018. Spokeswoman Sonia Choi said
Gilead is anticipating results from two trials in China in April.A leap in Gilead shares this month has added more than $12 billion to the company’s market value, a figure that far outstrips the
sales gains the company is likely to reap from the drug, according to some projections.Analysts at Bank of America expect remdesivir to result in one-time revenue of about $2.5 billion, at most.
Analyst Geoff Meacham said “remdesivir offers little lasting, meaningful” upside to Gilead’s bottom line given the economics of addressing epidemics or pandemics.Outbreaks of new or rare infectious
diseases can prompt a rush of efforts to find effective therapies, with trials often conducted in sometimes-chaotic field conditions. But not all work -- many of the drugs tested against Ebola during
outbreaks over the past decade failed, despite initial hopes they could save some patients from that deadly virus.(Updates with closing stock-price information in fourth paragraph. An earlier version
of this article corrected that remdesivir is not a vaccince candidate in the fifth paragraph.)To contact the reporters on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;Bailey
Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please
visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
>> Read more
>> Read more
How the IRS Knows If You Cheat on Your Taxes (Mon, 24 Feb 2020)
>> Read more
Italy, Iran Cases Jump; Drug Result Due in April: Virus Update (Tue, 25 Feb 2020)
(Bloomberg) -- Iran
reported a total of 15 deaths from the coronavirus, the most fatalities outside China. Italy, the outbreak’s epicenter in Europe, said infections in the Lombardy region rose to 206 from 172. The
country might seek flexibility on some budget targets.Earlier on Tuesday, South Korea reported 84 new infections for a total tally of 977, making it the country with most cases outside of China. The
U.S., Japan and Hong Kong issued travel warnings for South Korea, while the United Arab Emirates banned flights to all Iranian cities.The head of the World Health Organization had earlier called the
new cases “deeply concerning,” but said the outbreak isn’t yet a pandemic. China plans to release results from clinical trials of a Gilead Sciences Inc. drug in April.Key DevelopmentsChina death toll
2,663, up 71; total mainland cases at 77,658South Korea death toll at 10, countries issue travel warningsTrump administration seeks $2.5 billion in supplemental fundingHong Kong schools extend
closure, Indonesia plans stimulusClick VRUS on the terminal for news and data on the coronavirus and here for maps and charts. For analysis of the impact from Bloomberg Economics, click here.Mideast
Cases Rise, Flight Restrictions in Place (6 p.m. HK)Iran reported 34 new cases, for a total of 95, and a death toll of 15. Bahrain reported six new cases, while Kuwait has an additional three cases.
So far, there are about 130 confirmed cases in the Middle East and all of them are linked to Iran.The U.A.E. banned travel to all cities in Iran and has already suspended all flights to and from
China, except Beijing. Kuwait, which has already stopped flights to Iran, on Monday suspended travel to South Korea, Thailand, Italy and Iraq.Singapore Eases Rules for Chinese Workers in More Sectors
(6 p.m. HK)Singapore will loosen restrictions on Chinese work-permit holders in the country to help businesses in manufacturing and services industries that have been hit by labor disruptions during
the coronavirus outbreak.For six months beginning March 2, the Ministry of Manpower will allow companies in those sectors to hire Chinese workers who are already in the country, with the agreement of
their existing employers. Currently, businesses can only hire Chinese work-permit holders once they have left Singapore.Thailand’s Tourism Income Tumbled in January (5:55 p.m. HK)A slump in
Thailand’s foreign tourism income underlines the damage being inflicted on its economy. Receipts tumbled 3.6% in January from a year earlier to $6 billion), dragged down by a 10% slide in outlays by
Chinese visitors.HK Exports Slid Most in Decade in Jan. Ahead of Virus (5:26 p.m. HK)Hong Kong’s exports plummeted the most in more than a decade in January, as the government warned of further
weakness in the coming months with the full force of disruptions from the coronavirus outbreak still ahead. Exports sank 22.7% in January from year-ago levels to HK$269.4 billion ($34.6 billion), the
most since February 2009.Weihai to Quarantine People From Japan, S. Korea (5:22 p.m. HK)China’s Weihai city in Shandong province will quarantine people coming from Japan and South Korea for 14 days,
effective Feb. 25. People will be quarantined in hotels for free.Separately, Hangzhou, home to e-commerce giant Alibaba and other tech firms, will offer subsidies to people who choose to relocate to
the city for work during the epidemic. 85European Corporate Bond Market in Deep Freeze (4:50 p.m. HK)Global borrowers shunned Europe’s corporate debt market for a second day as a cluster of new
coronavirus cases in Italy sent yields sharply higher, bringing sales of new bonds to a near standstill.ING Groep’s downsized debt offering is the only deal priced so far this week, which had been
expected to deliver more than 20 billion euros ($22 billion) of sales, according to a Bloomberg News survey. Non-financial borrowers are nowhere to be seen, with Spain the only sovereign issuer
braving the market so far on Tuesday.Indonesia Unveils $718 Million Stimulus (4:46 p.m. HK)Indonesia will waive taxes of hotels and restaurants in ten tourist destinations for three months. State-run
oil retailer Pertamina will sell jet fuels to airlines at discounted prices, and the federal government will give grants to local governments as revenue from tourism slumpsGilead’s Drug Leads Global
Race for Treatment (3:40 p.m. H.K.)China said it will release results on April 27 of a clinical trial of Gilead Sciences’s remdesivir drug that the World Health Organization said may be the only
effective treatment so far for the disease.The trials of the experimental medication involved 761 patients in Wuhan, the city where the virus originated.Italian Tourist on Spanish Hotspot Tenerife
Tests Positive (2:27 p.m. H.K.)An Italian staying on the Spanish island of Tenerife tested positive for the virus and a second test to confirm the case will be carried out in Madrid, the government
said. The case would be Spain’s third and the first on the island, one of Europe’s top holiday destinations for winter sun. Tenerife, the largest of the Canary Islands, attracted more than 5.7
million tourists last year.The tourist, a doctor, had come from Lombardy, a region of northern Italy that is a focus of an outbreak of the virus, Efe news service reported. Spain’s two previously
confirmed patients no longer have the infection.Hong Kong Schools Extend Closure Until April 20 (2:12 p.m. H.K.)Hong Kong extended school closures by four weeks until at least the end of the Easter
break. The city will hold written university exams as scheduled from March 27 but postponed oral tests, Education Secretary Kevin Yeung said in a briefing.Students in the city, which has 81 confirmed
coronavirus cases, haven’t attended classes since the Lunar New Year break began in late January.In a Feb. 12 letter to Hong Kong Chief Executive Carrie Lam, the city’s international schools warned
that a prolonged shutdown could cause families to leave Hong Kong and force some schools to shut permanently.Japan Cruise Ship Death Reported (11:14 a.m. HK)A fourth passenger from the Diamond
Princess cruise ship in Japan has died, NHK reported.The patient was in his 80s and had the coronavirus, according to NHK. Three others from the ship have also died, though pneumonia was cited as the
cause of one of the deaths.The cruise ship that was quarantined for 14 days off of Yokohama has been the source of about 700 infections.Trump Administration Seeks $2.5 Billion to Battle Virus (9:41
H.K.)The Trump administration said it has asked Congress for $2.5 billion in supplemental funding to battle the spread of the coronavirus. More than $1 billion of the money would be go toward
creating, manufacturing and distributing a vaccine, according to a person familiar with the matter.The money would also be used to “support preparedness and response activities and to procure much
needed equipment and supplies,” said Rachel Semmel, a spokeswoman for the Office of Management and Budget.House Appropriations Committee Chair Nita Lowey said the requested sum “is woefully
insufficient.”Singapore’s Temasek Freezes Pay Amid Virus (9:35 a.m. H.K.)Temasek Holdings Pte, Singapore’s state-owned investment firm, said it will implement a company-wide wage freeze and ask
senior management to take bonus cuts and voluntary pay reductions starting in April amid the coronavirus outbreak.About 26% of Temasek’s holdings were in China as of March 2019, including
multibillion-dollar stakes in Alibaba Group Holding Ltd. and Industrial & Commercial Bank of China Ltd. With the money saved, Temasek said it will donate to staff volunteer initiatives and
support the community as needed through unspecified measures.CDC Warns Americans on Korean Travel (8:05 a.m. HK)The U.S. Centers for Disease Control and Prevention warned Americans to avoid all
non-essential travel to South Korea as the novel coronavirus is spreading widely throughout the community there.Older adults and people with chronic medical conditions may be at increased risk from
the pathogen, and there is limited access to adequate medical care in affected areas, the agency said. The level 3 warning, the CDC’s highest, matches the caution it previously placed on China.The
CDC previously issued lower-level alerts for Italy, Iran and Japan, telling travelers to take extra care and consider postponing non-essential travel.Singapore Air to Cut More Flights (7:59 a.m.
HK)Singapore Airlines will make more temporary adjustments to flights across its network due to weak demand because of the coronavirus outbreak, the company says on its website. The adjustments will
result in a 7.1% reduction in scheduled capacity from February to the end of May.\--With assistance from Charles Penty.To contact Bloomberg News staff for this story: Jeff Sutherland in Tokyo at
jsutherlan13@bloomberg.netTo contact the editors responsible for this story: Rachel Chang at wchang98@bloomberg.net, Adam MajendieFor more articles like this, please visit us at
bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
>> Read more
J.P. Morgan: 2 “Strong Buy” Healthcare Stocks With Over 50% Upside (Mon, 24 Feb 2020)
Digitization of the
world we live in has disrupted the healthcare industry, giving rise to the healthcare information technology (IT) segment of the market. The emergence of this space and the technology it offers has
transformed the way healthcare providers and organizations care for patients. Not to mention efficiency has improved dramatically. Demand for these digital solutions isn’t expected to slow anytime
soon, with Grand View Research predicting that the digital healthcare market will expand at a CAGR of 27%, reaching $509.2 billion by 2025.Bearing this in mind, investing firm J.P. Morgan took a look
at several healthcare IT names ahead of their upcoming fourth quarter earnings releases.“Sentiment on the group has been largely favorable, with the group up 12% since Q3 earnings in November vs the
remaining Healthcare Technology & Distribution group up 14% and the SPX 8%-plus,” analyst Anne Samuel commented.In the report, the firm highlights two tickers in particular that it believes can
not only deliver solid prints, but also reward investors through 2020 and beyond. After using TipRanks’ Stock Screener tool, we found out each boasts a “Strong Buy” consensus rating from the Street,
and has a substantial upside potential from the current share price. We’re talking more than 50% here.Health Catalyst Inc. (HCAT)With its cloud-based data platform, Health Catalyst offers data and
analytics solutions to healthcare organizations. As the company gears up for its February 27 earnings release, J.P. Morgan has high hopes.The investment banking firm's analyst, Anne Samuel, notes
that she will be focused on how many new Data Operating System (DOS) clients were added during the year as well as dollar-based retention. Additionally, Samuel highlights the fact that the company
thinks the Medicity conversion opportunity is approaching an inflection point in 2020 given that this past summer, cross-sell conversations kicked off.Based on Samuel’s estimates, the analyst expects
net new customers for 2019 to land at 14, which would reflect 28% year-over-year customer growth. In terms of 2020 guidance, she is forecasting 18 net new DOS subscription customers and 7% same-store
growth, amounting to 25% DOS subscription revenue growth. However, thanks to Medicity drag, the total revenue gain is expected to come in at 22%. As a result, this brings the 2020 revenue prediction
to $186 million, which falls in line with the consensus.While Samuel does point out that HCAT operates in a highly competitive environment and that there could be an expense shift of $200,00 from Q3
into Q4, her bullish thesis remains very much intact. “We see significant white space in an $8 billion TAM, with over 20% revenue growth driven by mid-teens annual customer wins. We estimate the
company reaches EBTIDA profitability in the next four years as a maturing customer base drives incremental leverage. The model is predictable with over 90% recurring revenue, 107% net dollar-based
retention, and a sticky customer base, never having lost an all-access customer,” the analyst explained.Taking all of this into consideration, Samuel maintained both her Overweight call and $50 price
target. Should this target be met, shares could be in for a twelve-month gain of 66%. (To watch Samuel’s track record, click here)Overall, it has been relatively quiet when it comes to other analyst
activity. In the last three months, only 3 analysts have issued ratings. However, as they were all Buys, the word on the Street is that HCAT is a Strong Buy. Based on the $48.33 average price target,
shares could climb 60% higher in the next twelve months. (See Health Catalyst stock analysis on TipRanks)Livongo Health Inc. (LVGO)Moving on to the firm’s next pick, we come across Livongo Health.
For patients battling chronic health conditions, its digital health platform makes it easy to access personalized digital guidance and health coaching through a smart connected device. While the
healthcare name has experienced significant volatility, the firm remains optimistic.Ahead of its Q4 earnings release on March 2, Samuel, who also covers this stock, wrote that LVGO already “blessed
Street numbers on its Q3 call for $276 million equating to 63% year-over-year growth.” She added, “Looking at the economic value added (EVA) that they reported in Q3, a 40% conversion rate on $208
million year-to-date EVA would equate to a 70% revenue growth run rate on our math.”When the results are announced, Samuel anticipates that the Street will be paying close attention to 2020 guidance
and the sustainability of rapid growth, noting that management stated 2020 will be an “investment year”. On top of this, the analyst is hoping for an update on enrollment, pipeline for new growth and
any changes in the competitive landscape.In terms of the fourth quarter figures, Samuel is calling for revenue of $49.4 million and an EBITDA loss of $5.5 million, both of which would land within the
guided range. For 2020, the analyst expects the company to guide for $281 million in revenue, a 66% increase if achieved, gross profit margins of 72% and a fiscal 2020 EBITDA loss of $25
million.Despite the EBITDA figure being in the red, Samuel believes LVGO will be able to reach operating income profitability in 2021. Additionally, the analyst argued, “The company is minimally
penetrated in a vast and growing chronic disease market, as more than half of the U.S. population has one or more chronic conditions and an additional 4,000 Americans are diagnosed with diabetes each
day. LVGO’s rapid growth profile is attractive, and unique in Healthcare IT with our model calling for an 85% revenue CAGR over the next 3 years as the company increases its member base.”In line with
her optimistic take, Samuel kept an Overweight rating and price target of $43 on the stock. This target conveys her confidence in LVGO’s ability to climb 55% higher in the next twelve months.What
does the rest of the Street think about LVGO? As it turns out, other analysts are on the same page. With 100% Street support, the message is clear: the stock is a Strong Buy. Not to mention the
$45.67 average price target implies 64% upside potential. (See Livongo stock analysis on TipRanks)
>> Read more
Gilead Surges After WHO Comments on Virus Drug Testing (Mon, 24 Feb 2020)
(Bloomberg) -- Gilead Sciences Inc.
shares gained Monday after a senior World Health Organization official said the company’s experimental drug may be the best bet to find a treatment for the new coronavirus spreading around the
globe.Gilead’s compound, remdesivir, has been rushed into a clinical trial in China, where the illness has infected tens of thousands of people. WHO officials have said results could be available
within weeks.Remdesivir is the “one drug right now that we think may have efficacy,” Bruce Aylward, an assistant director-general at the World Health Organization, said at a briefing in Beijing. WHO
officials and international scientists are in the country assessing the outbreak.Gilead shares rose 4.6% to $72.90 on Monday, the highest closing level since October 2018. Spokeswoman Sonia Choi said
Gilead is anticipating results from two trials in China in April.A leap in Gilead shares this month has added more than $12 billion to the company’s market value, a figure that far outstrips the
sales gains the company is likely to reap from the drug, according to some projections.Analysts at Bank of America expect remdesivir to result in one-time revenue of about $2.5 billion, at most.
Analyst Geoff Meacham said “remdesivir offers little lasting, meaningful” upside to Gilead’s bottom line given the economics of addressing epidemics or pandemics.Outbreaks of new or rare infectious
diseases can prompt a rush of efforts to find effective therapies, with trials often conducted in sometimes-chaotic field conditions. But not all work -- many of the drugs tested against Ebola during
outbreaks over the past decade failed, despite initial hopes they could save some patients from that deadly virus.(Updates with closing stock-price information in fourth paragraph. An earlier version
of this article corrected that remdesivir is not a vaccince candidate in the fifth paragraph.)To contact the reporters on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net;Bailey
Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please
visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
>> Read more
Print